METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS

• US 20110229921A1
• Filed: 06/09/2010
• Published: 09/22/2011
• Est. Priority Date: 03/18/2010
• Status: Abandoned Application

• Current Assignee: Abbott Laboratories
• Original Assignee: Abbott Laboratories
• Inventors: Hebbar, Sudarshan, Doss, Robert C.
• Application Number:
  US12/796,794
• Publication Number:
  US 20110229921A1
• Time in Patent Office: Days
• US Class Current: 435/23
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

A method of prognosticating cadaveric kidney transplant function in a patient; a method of prognosticating cadaveric kidney transplant function in a patient diagnosed with DGF; a method of assessing risk of DGF in a patient, who has been diagnosed with EGF; and a kit comprising at least one component for assaying urine from a patient for NGAL and instructions for assaying the urine for NGAL and assessing cadaveric kidney transplant function or risk of DGF in the patient.

Claims

1. A method of prognosticating cadaveric kidney transplant function in a patient, which method comprises:

assaying urine samples from the patient for urinary neutrophil gelatinase-associated lipocalin (uNGAL) to allow detection of a change in the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at within about 24 hours before cadaveric kidney transplantation, wherein assaying comprises detecting the level of uNGAL in the urine sample, wherein;

detecting a decrease in the level of uNGAL of less than or equal to about 55% in the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at within about 24 hours before cadaveric kidney transplantation predicts delayed graft function (DGF), whereas detecting a decrease in the level of uNGAL of greater than about 55% in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at within about 24 hours before cadaveric kidney transplantation predicts early graft function (EGF),

whereupon cadaveric kidney transplant function in a patient is prognosticated.

2. The method of claim 1, which further comprises determining the volume of urine voided by the patient within about 24 hours of transplantation, wherein a volume less than about one liter indicates DGF and a volume greater than about one liter indicates EGF.

3. The method of claim 1, wherein detecting a decrease in the level of uNGAL of less than or equal to about 20% in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at within about 24 hours before cadaveric kidney transplantation predicts DGF lasting more than about 14 days.

4. The method of claim 3, which further comprises:

assaying urine samples from the patient for uNGAL to allow detection of a change in the level of uNGAL in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation, wherein assaying comprises detecting the level of uNGAL in the urine sample, wherein;

detecting an increase in the level of uNGAL in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation further predicts DGF lasting more than about 14 days.

5. The method of claim 1, wherein detecting a decrease in the level of uNGAL of at least about 20% and less than about 35% in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at within about 24 hours before cadaveric kidney transplantation predicts DGF lasting less than about 14 days.

6. The method of claim 5, which further comprises:

assaying urine samples from the patient for uNGAL to allow detection of a change in the level of uNGAL in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation, wherein assaying comprises detecting the level of uNGAL in the urine sample,

wherein;

detecting a decrease in the level of uNGAL of at least about 30% in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation predicts DGF lasting≦

7 days,

and detecting a decrease in the level of uNGAL of less than about 10% in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation predicts DGF lasting from about 8 days to about 14 days.

7. A method of prognosticating cadaveric kidney transplant function in a patient diagnosed with DGF, which method comprises:

assaying urine samples from the patient for uNGAL to allow detection of a change in the level of uNGAL in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation, wherein assaying comprises detecting the level of uNGAL in the urine sample,

wherein;

detecting a decrease in the level of uNGAL of at least about 30% in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation predicts DGF lasting≦

7 days,

detecting a decrease in the level of uNGAL of less than about 10% in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation predicts DGF lasting from about 8 days to about 14 days, or

detecting an increase in the level of uNGAL in a urine sample from the patient at about 72 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation predicts DGF lasting longer than about 14 days,

whereupon kidney transplant function in a patient diagnosed with DGF is prognosticated.

8. A method of assessing risk of DGF in a patient, who has been diagnosed with EGF based on (i) the volume of urine voided by the patient within about 24 hours of cadaveric kidney transplantation being at least about one liter and/or (ii) the level of creatinine in the plasma of the patient at about 24 hours after cadaveric kidney transplantation being lower than the level of creatinine in the plasma of the patient within about 24 hours before cadaveric kidney transplantation, which method comprises:

assaying urine samples from the patient for uNGAL to allow detection of a change in the level of uNGAL in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient within about 24 hours before cadaveric kidney transplantation, wherein assaying comprises detecting the level of uNGAL in the urine sample and;

detecting a decrease in the level of uNGAL of less than about 55% in a urine sample from the patient at about 24 hours after cadaveric kidney transplantation in comparison to the level of uNGAL in a urine sample from the patient within about 24 hours before cadaveric kidney transplantation predicts risk of DGF,

whereupon risk of DGF in a patient diagnosed with EGF is assessed.

9. A kit comprising at least one component for assaying urine from a patient, who has received a cadaveric kidney transplant, has received a cadaveric kidney transplant and has been diagnosed with EGF, or is about to receive a cadaveric kidney transplant, for neutrophil gelatinase-associated lipocalin (NGAL) and instructions for assaying the urine for NGAL and assessing kidney transplant function or risk of DGF in the patient.